The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing both non-hormonal contraceptive and reproductive health related product development. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). The long-term objective is to enable a preclinical candidate for IND/IDE study(ies) that offers a safe therapeutic option in the field of contraception, and/or reproductive health related indications (pending contractor availability and available funding).
Deadlines:
- Letter of Intent Due Date(s): 30 days before application due date.
- Application Due Date(s): October 3, 2023, April 3, 2024, October 3, 2024, April 3, 2025, October 3, 2025, April 3, 2026
PAR-23-193 Expiration Date April 04, 2026